Log in

IPSEN S A/S News Headlines (OTCMKTS:IPSEY)

$18.21
+0.21 (+1.17 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$18.21
Now: $18.21
$18.56
50-Day Range
$17.49
MA: $20.61
$22.91
52-Week Range
$17.20
Now: $18.21
$35.97
Volume3,204 shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio9.63
Dividend YieldN/A
BetaN/A

Headlines

IPSEN S A/S (OTCMKTS IPSEY) News Headlines

Source:
DateHeadline
Ipsen S.A. 2019 Q4 - Results - Earnings Call PresentationIpsen S.A. 2019 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 13 at 12:18 PM
Ipsen Presents Its 2019 Results, Provides 2020 Guidance and Updates 2022 Financial OutlookIpsen Presents Its 2019 Results, Provides 2020 Guidance and Updates 2022 Financial Outlook
finance.yahoo.com - February 13 at 1:08 AM
Credit Suisse Group Upgrades IPSEN S A/S (OTCMKTS:IPSEY) to "Neutral"Credit Suisse Group Upgrades IPSEN S A/S (OTCMKTS:IPSEY) to "Neutral"
www.americanbankingnews.com - February 11 at 7:55 AM
IPSEN S A/S (IPSEY) Scheduled to Post Quarterly Earnings on ThursdayIPSEN S A/S (IPSEY) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - February 6 at 2:59 AM
IPSEN S A/S (OTCMKTS:IPSEY) Receives Average Recommendation of "Hold" from BrokeragesIPSEN S A/S (OTCMKTS:IPSEY) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 3 at 6:36 AM
Peptide Therapeutics Market 2020 Size, Statistics, Growth, Revenue, Analysis & Trends Industry Forecast Report -2025|Market Research EnginePeptide Therapeutics Market 2020 Size, Statistics, Growth, Revenue, Analysis & Trends Industry Forecast Report -2025|Market Research Engine
www.marketwatch.com - January 30 at 9:31 AM
Ipsen up 4% on diminished generic threat to SomatulineIpsen up 4% on diminished generic threat to Somatuline
seekingalpha.com - January 29 at 12:47 PM
LIVE MARKETS-Opening snapshot: drug trials knock out Ipsen and HK drags RemyLIVE MARKETS-Opening snapshot: drug trials knock out Ipsen and HK drags Remy
www.lse.co.uk - January 25 at 1:36 PM
Ipsen hits potential roadblock with palovaroteneIpsen hits potential roadblock with palovarotene
seekingalpha.com - January 25 at 1:36 PM
Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteriaIpsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria
finance.yahoo.com - January 24 at 5:16 AM
Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical OfficerIpsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer
finance.yahoo.com - January 14 at 1:15 AM
Ipsen: Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsyIpsen: Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy
finance.yahoo.com - January 6 at 1:47 AM
Is Ipsen S.A. (EPA:IPN) Overpaying Its CEO?Is Ipsen S.A. (EPA:IPN) Overpaying Its CEO?
finance.yahoo.com - January 3 at 4:36 PM
Ipsen Announces Its Corporate Agenda For 2020Ipsen Announces Its Corporate Agenda For 2020
finance.yahoo.com - December 19 at 1:35 PM
Ipsens CEO Resigns, to Join Ferring UnitIpsen's CEO Resigns, to Join Ferring Unit
www.nytimes.com - December 18 at 8:16 AM
Ipsen Announces Departure of David Meek as Chief Executive OfficerIpsen Announces Departure of David Meek as Chief Executive Officer
finance.yahoo.com - December 18 at 8:16 AM
Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the CompanyIpsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company
finance.yahoo.com - December 12 at 2:12 PM
FDA places partial clinical hold on studies of Ipsens palovaroteneFDA places partial clinical hold on studies of Ipsen's palovarotene
seekingalpha.com - December 6 at 12:22 PM
Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety ConcernsIpsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns
finance.yahoo.com - December 6 at 12:22 PM
Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 StudiesIpsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies
finance.yahoo.com - December 6 at 1:36 AM
Does Ipsen S.A. (EPA:IPN) Have A Place In Your Dividend Portfolio?Does Ipsen S.A. (EPA:IPN) Have A Place In Your Dividend Portfolio?
finance.yahoo.com - December 4 at 7:25 AM
Health Canada approves CABOMETYX™ (cabozantinib) Giving Physicians and Adult Patients a New Second-Line Option in the Fight Against Advanced Hepatocellular CarcinomaHealth Canada approves CABOMETYX™ (cabozantinib) Giving Physicians and Adult Patients a New Second-Line Option in the Fight Against Advanced Hepatocellular Carcinoma
finance.yahoo.com - November 12 at 9:15 AM
Do Ipsen's (EPA:IPN) Earnings Warrant Your Attention?Do Ipsen's (EPA:IPN) Earnings Warrant Your Attention?
finance.yahoo.com - November 6 at 9:02 AM
Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and DevelopmentIpsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development
finance.yahoo.com - November 5 at 8:07 AM
Proposed reclassification of Ipsen shares held by MayroyProposed reclassification of Ipsen shares held by Mayroy
finance.yahoo.com - November 5 at 12:01 AM
Ipsen S.A. 2019 Q3 - Results - Earnings Call PresentationIpsen S.A. 2019 Q3 - Results - Earnings Call Presentation
seekingalpha.com - October 24 at 12:48 PM
Ipsen and Blueprint Medicines Announce Exclusive Global License Agreement to Develop and Commercialize BLU-782 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)Ipsen and Blueprint Medicines Announce Exclusive Global License Agreement to Develop and Commercialize BLU-782 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
finance.yahoo.com - October 16 at 7:20 AM
Health Canada approves Ipsens Cabometyx for aRCC treatmentHealth Canada approves Ipsen's Cabometyx for aRCC treatment
seekingalpha.com - October 15 at 2:22 PM
Should We Be Delighted With Ipsen S.A.'s (EPA:IPN) ROE Of 20%?Should We Be Delighted With Ipsen S.A.'s (EPA:IPN) ROE Of 20%?
finance.yahoo.com - October 14 at 6:09 AM
FDA OKs expanded use of Ipsens DysportFDA OKs expanded use of Ipsen's Dysport
seekingalpha.com - September 26 at 9:16 AM
Is Ipsen S.A.'s (EPA:IPN) P/E Ratio Really That Good?Is Ipsen S.A.'s (EPA:IPN) P/E Ratio Really That Good?
finance.yahoo.com - September 24 at 8:02 AM
Ipsens Dysport shows positive effect in post-market limb spasticity studyIpsen's Dysport shows positive effect in post-market limb spasticity study
seekingalpha.com - September 23 at 5:00 PM
 Ipsen to Present New Data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019) Ipsen to Present New Data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)
finance.yahoo.com - September 21 at 3:28 PM
Ipsens Onivyde shows positive action in mid-stage lung cancer studyIpsen's Onivyde shows positive action in mid-stage lung cancer study
seekingalpha.com - September 9 at 2:03 PM
Estimating The Fair Value Of Ipsen S.A. (EPA:IPN)Estimating The Fair Value Of Ipsen S.A. (EPA:IPN)
finance.yahoo.com - September 6 at 12:58 PM
Ipsen (EPA:IPN) Has A Pretty Healthy Balance SheetIpsen (EPA:IPN) Has A Pretty Healthy Balance Sheet
finance.yahoo.com - August 20 at 9:15 AM
Ipsen S.A. (EPA:IPN): The Best Of Both WorldsIpsen S.A. (EPA:IPN): The Best Of Both Worlds
finance.yahoo.com - August 4 at 10:22 AM
Ipsen S.A. ADR (IPSEY) CEO David Meek on Q2 2019 Results - Earnings Call TranscriptIpsen S.A. ADR (IPSEY) CEO David Meek on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - July 28 at 10:37 AM
Ipsen S.A. 2019 Q2 - Results - Earnings Call SlidesIpsen S.A. 2019 Q2 - Results - Earnings Call Slides
seekingalpha.com - July 25 at 12:54 PM
Ipsen S.A. (EPA:IPN): Will The Growth Last?Ipsen S.A. (EPA:IPN): Will The Growth Last?
finance.yahoo.com - July 18 at 11:24 AM
Ipsen and Servier Announce Initial Phase 1/2 Clinical Data Evaluating Liposomal Irinotecan (ONIVYDE®) as an Investigational First-line Treatment for Metastatic Pancreatic Cancer at ESMO 21st World Congress on Gastrointestinal CancerIpsen and Servier Announce Initial Phase 1/2 Clinical Data Evaluating Liposomal Irinotecan (ONIVYDE®) as an Investigational First-line Treatment for Metastatic Pancreatic Cancer at ESMO 21st World Congress on Gastrointestinal Cancer
finance.yahoo.com - July 5 at 10:35 AM
Is Ipsen S.A. (EPA:IPN) Excessively Paying Its CEO?Is Ipsen S.A. (EPA:IPN) Excessively Paying Its CEO?
finance.yahoo.com - July 3 at 10:45 AM
FDA OKs new pre-filled syringe for Ipsens Somatuline DepotFDA OKs new pre-filled syringe for Ipsen's Somatuline Depot
seekingalpha.com - June 24 at 6:41 PM
Ipsen Celebrates Opening of New Cambridge Headquarters with Day of ServiceIpsen Celebrates Opening of New Cambridge Headquarters with Day of Service
finance.yahoo.com - June 20 at 4:53 PM
How Much Of Ipsen S.A. (EPA:IPN) Do Institutions Own?How Much Of Ipsen S.A. (EPA:IPN) Do Institutions Own?
finance.yahoo.com - June 10 at 11:30 AM
Ipsens Dysport granted a licence update in UKIpsen's Dysport granted a licence update in UK
seekingalpha.com - June 5 at 10:37 AM
Ipsens Dysport® (Clostridium Botulinum Type a Toxin-haemagglutinin Complex) Becomes First and Only Botulinum Toxin Type A to be Granted a Licence Update for Administration by Healthcare Professionals, Such as Physiotherapists, in the UKIpsen's Dysport® (Clostridium Botulinum Type a Toxin-haemagglutinin Complex) Becomes First and Only Botulinum Toxin Type A to be Granted a Licence Update for Administration by Healthcare Professionals, Such as Physiotherapists, in the UK
finance.yahoo.com - June 5 at 10:37 AM
KNDL 2019-KNSQ Mortgage Trust -- Moodys assigns definitive ratings to Five CMBS classes of KNDL 2019-KNSQ Mortgage TrustKNDL 2019-KNSQ Mortgage Trust -- Moody's assigns definitive ratings to Five CMBS classes of KNDL 2019-KNSQ Mortgage Trust
finance.yahoo.com - May 30 at 4:55 PM
Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?
finance.yahoo.com - May 24 at 10:48 AM
Ipsen to Host an Investor Day to Highlight Its Innovative R&D Pipeline and Provide Financial Outlook for 2022Ipsen to Host an Investor Day to Highlight Its Innovative R&D Pipeline and Provide Financial Outlook for 2022
finance.yahoo.com - May 14 at 11:12 AM
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: Portfolio Manager

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel